Related Experiment Video
Updated: May 2, 2026
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
Extraintestinal manifestations in Korean patients with inflammatory bowel disease: A nationwide population-based
Sung Sil Park1,2, Yun Jin Kim3,4, Byung Kyu Ahn1,2
1Department of Surgery, Hanyang University Hospital, Seoul, Korea.
Background:
Extraintestinal manifestations (EIMs) significantly contribute to morbidity in individuals with inflammatory bowel disease (IBD); however, population-based East Asian data remain limited. We evaluated EIM burden in a nationwide Korean IBD cohort.
Methods:
This nationwide retrospective cohort study was conducted using data from the Korean National Health Insurance Service between 2005 and 2017. Individuals with ulcerative colitis (UC) or Crohn's disease (CD) were identified using the International Classification of Diseases-10th Edition and rare intractable disease codes. EIM incidence, associated risk factors, interval from IBD diagnosis to EIM onset, and trends by sex and age were examined.
Results:
Among 69 414 individuals with IBD (48 689 UC, 20 725 CD), 42.23% developed at least 1 EIM. Dermatologic manifestations were the most common (17.02%), followed by musculoskeletal (16.36%), hepatopancreaticobiliary (15.48%), and ophthalmologic (7.83%) manifestations. Low socioeconomic status, smoking history, female sex, and higher Charlson Comorbidity Index scores independently correlated with EIM development in UC (hazard ratios of 2.14, 1.18, 1.15, and 1.08, respectively) and CD (hazard ratios of 1.98, 1.20, 1.18, and 1.09, respectively). Most EIMs developed within 4 to 6 years postdiagnosis, with musculoskeletal EIMs occurring earliest (median 42.9 months [interquartile range: 10.3-89.5 months]). Annual EIM incidence increased steadily over time across all age groups.
Conclusions:
EIMs affected 42.23% of Korean individuals with IBD, most frequently appearing 4 to 6 years postdiagnosis. Low socioeconomic status, smoking history, female sex, and higher Charlson Comorbidity Index scores consistently correlated with EIM occurrence, and incidence increased steadily over time, highlighting the need for sustained, personalized monitoring and timely intervention.
Related Concept Videos
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:26Inflammatory Bowel Disease I: Introduction
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:25Inflammatory Bowel Disease III: Crohn's Disease